<DOC>
	<DOCNO>NCT00014573</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy bone marrow peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Vaccines make person 's white blood cell tumor cell may make body build immune response kill tumor cell . Interleukin-2 may stimulate person 's white blood cell kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy vaccine therapy follow bone marrow peripheral stem cell transplantation interleukin-2 treating patient recurrent refractory brain cancer .</brief_summary>
	<brief_title>Chemotherapy Vaccine Therapy Followed Bone Marrow Peripheral Stem Cell Transplantation Interleukin-2 Treating Patients With Recurrent Refractory Brain Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine effectiveness induction paclitaxel cyclophosphamide follow autologous tumor cell vaccine sargramostim ( GM-CSF ) follow high-dose chemotherapy cisplatin , cyclophosphamide , carmustine , autologous bone marrow peripheral blood stem cell transplantation , interleukin-2 patient recurrent refractory primary high-grade brain tumor . - Determine safety toxicity regimen patient . - Determine specific quantitative cellular response elicit patient treated regimen . OUTLINE : After partial surgical resection tumor , patient receive induction chemotherapy comprise paclitaxel IV 3 hour cyclophosphamide IV 1 hour day 1 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 3 continue peripheral blood stem cell ( PBSC ) bone marrow collection complete . After collection PBSC bone marrow , patient receive autologous tumor cell vaccine sargramostim ( GM-CSF ) SC every 2 week 5 vaccination . Two week last vaccination , patient undergo second leukapheresis collect lymphocytes . After completion second leukapheresis , patient receive high-dose chemotherapy comprise cisplatin IV continuously 24 hour day -5 , cyclophosphamide IV 1 hour day -5 , -4 , -3 , carmustine IV 2 hour day -2 . Patients undergo autologous bone marrow PBSC transplantation day 0 . Patients receive G-CSF IV daily begin day 0 continue blood count recover . Approximately 12 week bone marrow PBSC transplantation , patient receive autologous lymphocyte IV 2-5 hour . Patients also receive interleukin-2 IV every day 10 day . Patients follow 18 , 24 , 36 , 40 , 52 week . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm active recurrent refractory primary highgrade brain tumor Tumor must surgically accessible Bidimensionally measurable disease clinical exam , CT scan , xray Disease must outside previously irradiated field progress developed radiotherapy Previously treat metastatic bony lesion consider measurable No previously irradiate metastatic disease site unless response clear progression image PATIENT CHARACTERISTICS : Age : 65 Performance status : CALGB 02 Life expectancy : More 3 month Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Liver function less 2.5 time normal unless due disease No active hepatitis B C Renal : Creatinine le 1.5 mg/dL Creatinine clearance great 60 mL/min Cardiovascular : Left ventricular ejection fraction great 50 % MUGA 2D echocardiogram Electrocardiogram normal Pulmonary : FEV1 DLCO great 50 % predict OR Clearance pulmonologist Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No serious underlie comorbid disease medical psychiatric factor would preclude study Able wean steroid surgery PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Recovered prior conventional chemotherapy Endocrine therapy : No concurrent steroid therapy mass effect Radiotherapy : See Disease Characteristics Recovered prior conventional radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>adult choroid plexus tumor</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>